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Purpose: To investigate the effects of brimonidine, an α-2-adrenergic agonist, on barrier function in ARPE-19 cells 
by measuring transepithelial resistance (TER).
Methods: ARPE-19 cells were cultured into a confluent monolayer on a microporous filter. Brimonidine was added 
to the apical medium, and the barrier function of the cells was evaluated by measuring TER. A subset of cells was 
treated under hypoxic conditions, and the TER changes observed upon administration of brimonidine were com-
pared to those observed in cells in normoxic conditions.
Results: The ARPE cell membrane reached a peak resistance of 29.1±7.97 Ωcm
2 after four weeks of culture. The 
TER of the cells treated under normoxic conditions increased with brimonidine treatment; however, the TER of 
the cells treated under hypoxic conditions did not change following the administration of brimonidine.
Conclusions: Barrier function in ARPE-19 cells increased with brimonidine treatment. Understanding the exact 
mechanism of this barrier function change requires further investigation.
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The retinal pigment epithelium (RPE) plays an essential 
role in maintaining the viability and functionality of the neu-
ral retina and, among other functions, prevents the neuro-
sensory retina from accumulating extracellular fluid in the 
subretinal space [1].
The human RPE cell line (ARPE-19) has structural and 
functional properties characteristic of RPE cells in vivo and 
therefore makes this cell line valuable for in vitro studies of 
retinal pigment epithelium physiology. These cells were first 
described as developing into highly differentiated, polarized 
monolayers and exhibiting features of a polarized and differ-
entiated epithelium [2,3]. The measurement of transepithelial 
resistance (TER) in cultured ARPE cells has been used to 
evaluate the barrier function of RPE cells [4,5].
Adrenergic α and β receptors have been identified in cul-
tured human RPE cells; they participate in membrane perme-
ability and membrane potential in ARPE cells [6]. Also, it 
has been reported that α-2-receptors are expressed in RPE- 
choriocapillaries, though the exact function of this α receptor 
has not yet been elucidated [7].
Brimonidine is a selective α-2-adrenergic agonist that has 
recently been approved for the long-term treatment of ele-
vated intraocular pressure due to open angle glaucoma or oc-
ular hypertension. In addition, it reaches significant concen-
trations with clinical dosing and exhibits a neuroprotective 
effect in animal models [8]. 
In the present study, we measured the TER in cultured 
ARPE cells in order to investigate the role of adrenergic α
-2-agonists with respect to barrier function in the RPE. 
Materials and Methods
Cell culture
The human RPE cell line, ARPE-19 cells were purchased 
from the American Type Culture Collection (Rockville, MD, 
USA). The cells were passaged and propagated using a slight Korean J Ophthalmol Vol.24, No.3, 2010
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Fig. 1. Changes of transepithelial resistance (TER) according to the 
culture periods. The TER was highest at 4 weeks of culture and de-
creased thereafter.
modification of the technique described by Dunn et al [2]. In 
brief, the cells were cultured in medium (DMEM/F12; Gibco 
BRL, Grand Island, NY, USA) containing 10% fetal bovine 
serum (FBS; ThermoTrace, Melbourne, Australia) in a hu-
midified incubator at 37°C in 5% CO2. Media were changed 
twice a week. 
The ARPE cells were seeded at a density of 1.66×105 
cells/cm
2 in DMEM/F-12 culture medium and supplemented 
with 100 U/mL penicillin-streptomycin, 2 mM L-glutamine, 
and 1% FBS on a microporous filter (Transwell; Costar 
Corning, Corning, NY, USA) until the cells cultured to confluence. 
For the hypoxic cell group, the ARPE-19 cells were trans-
ferred to a hypoxic chamber containing 5% CO2, 94% N2 and 
1% O2 24 hours prior to TER measurement.
Measurement of transepithelial electrical resistance
The TER was measured using an epithelial volt-ohmmeter 
(EVOM; World Precision Instruments, Sarasota, FL, USA). 
The TER of the filter alone was measured as background and 
was subtracted from the TER obtained with the filters and 
ARPE-19 cells. Net TER measurements were calculated by 
subtracting the value of a blank, laminin-coated filter without 
cells from the experimental value. Final resistance-area 
products (Ω×cm
2) were obtained by multiplication with the 
effective growth area. 
The ARPE cells were cultured and the TER was measured 
every week for up to six weeks in order to determine the opti-
mal incubation time for yielding the highest TER. The via-
bility of the cells was assessed using trypan blue dye.
Brimonidine was purchased from Sigma Chemicals (St 
Louis, MO, USA) and was dissolved in dimethyl sulfoxide 
(DMSO) to a concentration of 50 mM and diluted to 0.01, 
0.1, or 1 uM in DMEM/F12 medium containing 1% FBS 
just prior to use. The baseline TER was measured before ad-
ministration of brimonidine. Immediately following this, 50 uL 
brimonidine solution was added to the apical chamber, and 
50 uL culture media was taken out of the apical chamber si-
multaneously so that the concentration of brimonidine in 
the apical chamber reached 1, 10, or 100 nM (depending on 
the initial concentration) and so that the fluid volume of the 
apical chamber was not altered. To determine the optimal 
concentration of brimonidine, changes in TER were measured 
every 10 seconds for the first minute following exposure to 
each concentration of brimonidine and at 2, 3, and 5 mi-
nutes thereafter. Measurements were repeated at least three 
times for each well and for five wells of each concentration.
Changes in TER following administration of brimonidine 
to both the normoxic and hypoxic cell cultures were meas-
ured at every 10 seconds for the first minute following ex-
posure and at 2, 3, 5, 10, 20, 30, and 120 minutes thereafter. 
Measurements were repeated at least three times for each 
well, and each experiment was repeated in 11 different 
wells. 
Statistical analysis
The results were expressed as mean value±SD. Comparison 
of the TERs between the normoxic and hypoxic group was 
performed using the Mann-Whitney U-test. Changes in the 
TER from the baseline value following treatment with bri-
monidine were analyzed using the Wilcoxon signed rank test. 
Statistical significance was accepted at the p＜0.05 level. 
Statistical analyses were performed using SPSS ver. 17.0 
(SPSS Inc., Chicago, IL, USA).
Results
The monolayer of cells developed a resistance of approx-
imately 20.9±5.40 Ωcm
2(n=5)  after two weeks of culture 
and reached a peak resistance of 29.1±7.97 Ωcm
2 (n=5) after 
four weeks of culture. The TER had decreased to 25.1±7.21 
Ωcm
2 (n=5) after six weeks of culture (Fig. 1). The viability 
of the ARPE cells was greater than 97% at all measuring 
points.
When the ARPE monolayer was treated with various con-
centrations of brimonidine at four weeks of culture, the 10 nM 
concentration of brimonidine induced the greatest change in 
TER, although it was not statistically significant.  
The normoxic ARPE monolayer was treated with a 10 nM 
concentration of brimonidine at four weeks of culture; this 
was believed to be the optimal concentration and culture pe-
riod for TER measurement. Treatment with brimonidine re-
sulted in an increase in TER (Fig. 2). Pretreatment values of 
TER (mean 29.1±7.97 Ωcm
2) increased to 31.5±6.0 Ωcm
2 1 
minute after treatment (p=0.05, n=11, Wilcoxon signed rank 
test) and maintained this level 30 minutes (32.3±9.16 Ωcm
2, 
p=0.038) after exposure. Thereafter, the TER decreased until 
it returned to its baseline level two hours following brimoni-
dine treatment.JH Park, et al. Effect of Brimonidine on RPE Barrier Function
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Fig. 2. The effects of brimonidine on transepithelial resistance in 
polarized ARPE‐19 monolayers cultured in normoxic condition. 
ARPE‐19 cells were treated with 10 nM brimonidine and trans-
epithelial resistance (TER) was measured at indicated time points. 
Data are mean±2SD (n=14). The TER values showed significant 
increase compared to the pre‐treatment values immediately after the 
exposure to brimonidine and up to 30 minutes. Thereafter, the TER 
decreased until it returned to its baseline level two hours following 
brimonidine treatment.
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Fig. 3. The effects of brimonidine on transepithelial resistance (TER)
in polarized ARPE‐19 monolayers cultured in hypoxic condition. 
The TER of the hypoxic ARPE monolayer did not change in the two 
hours following exposure to brimonidine. 
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Fig. 4. The effects of brimonidine on tranepithelail resistance (TER) 
in polarized ARPE‐19 monolayers cultured in normoxic and hypoxic
conditions. The ARPE‐19 monolayers treated in the hypoxic 
chamber showed no increment of TER after the treatment of 
brimonidine (p=0.038 compared to the baseline value).
In contrast, the TER of the hypoxic ARPE monolayer did 
not change in the two hours following exposure to brimoni-
dine (Fig. 3). Changes in the TER at 3 minutes post-ex-
posure, when the TER increase was greatest in the normoxic 
group, were compared between the normoxic and hypoxic 
groups (Fig. 4).
Discussion
This study indicates that the TER of an ARPE-19 mono-
layer can be increased by treatment with a nanomolar amount 
of apical brimonidine. However, this effect was not repro-
duced in the ARPE monolayer treated under hypoxic 
conditions. These results suggest that α-2 receptors play a 
role in maintaining barrier function in the RPE.
The RPE passively and actively transports fluid in the sub-
retinal to choroidal direction; this RPE fluid “pump” function 
is thought to play a major role in reabsorption of subretinal 
fluid and in promoting and maintaining retinal attachment 
[9]. Therefore, the RPE membrane is a potential target for 
small therapeutic molecules that bind membrane receptors 
and activate fluid absorption from the subretinal space. 
Several studies have reported that α-2-adrenergic receptors 
are present in the human ciliary body, retinal pigmented epi-
thelium–choriocapillaris, iris, and neurosensory retina [10,11]. 
Quinn and associates reported that adrenergic agonists, in-
cluding isoproterenol and epinephrine, activate ion transport 
at the apical membrane of the human fetal RPE [6]. We hy-
pothesize that the presence of α-2-receptors in the RPE could 
change the barrier function of the RPE membrane.
Brimonidine, an α-2-adrenergic receptor agonist, has been 
employed in the clinical setting of glaucoma because of its 
therapeutic potential for reducing intraocular pressure (IOP) 
by aqueous suppression and enhanced uveoscleral outflow. 
In addition to these IOP-lowering effects, several recent in-
vestigations in animal models suggest that brimonidine may 
exert a neuroprotective effect on retinal ganglion cells by 
preventing cell death secondary to ischemic injury [8,12]. A 
recent clinical pilot study suggests a trend toward slower pro-
gression of retinal dystrophy when treated with topical bri-Korean J Ophthalmol Vol.24, No.3, 2010
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monidine [13]. Furthermore, topically applied brimonidine 
can reach the back of the eye at nanomolar concentrations 
sufficient to activate α-2 adrenergic receptors. This yields 
obvious advantages for the treatment of various retinal dis-
eases in clinical settings [14]. 
Following exposure to brimonidine, there was no increase 
in the TER of the ARPE membrane culture subjected to hy-
poxic conditions. This result suggests that hypoxia can in-
duce dysfunction of active ion transport at the apical mem-
brane of the ARPE. 
Some studies have reported that DMSO at concentrations 
of 1% or 10% can induce TER changes in various cell mem-
branes [15,16]. In contrast, Cui et al. [5] showed that 0.05% 
DMSO did not alter TER in cultured ARPE. In this study, the 
final concentration of DMSO was 1/250 of that used in the 
former study, and its effect on TER was therefore insignificant. 
One limitation of this study is that we could not elucidate 
the mechanisms of TER change in the ARPE membrane. An 
analysis of ion transfer and permeability testing could have 
possibly supported the TER changes observed in this study. 
Although the exact mechanism remains unclear, brimoni-
dine enhanced the barrier function in ARPE-19 cells in the 
present study. The specific effects of brimonidine on the ac-
tion of ion pumps require further investigation.
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